Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 22, Issue 11, Pages 1367-1375Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543776.2012.714371
Keywords
anti-tumor; calcium phosphate; hybrid nanocomplex; self-assembled nanoparticles; targeted drug delivery; zoledronic acid
Categories
Ask authors/readers for more resources
The focus of this patent was to manipulate the pharmacokinetic profile of an amino-bisphosphonate (zoledronic acid, ZOL) to make it desirable for antitumor uses. This patent disclosed a unique drug loading strategy that was inspired by gene delivery vehicles based on similar materials (calcium phosphate, CaP). The promise of this drug delivery system (DDS) lies not only in a 44% in vivo inhibition of tumor growth compared with free drug, but also in the low toxicity of the drug which guarantees a dosage regimen with higher doses and longer course of treatment. Also, the disclosed DDS has the potential to be further upgraded. In this patent evaluation, the state of the art in the field of CaP-based drug carrier and the novelty of this invention will be discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available